Skip to main content Skip to main content
Private-Credit Borrower

Simtra BioPharma Solutions

Acquisition holding entity ("Bidco" = the buyer vehicle in a leveraged buyout) tied to Bamboo, a technology-enabled managing general agent (MGA) for homeowners insurance. As an MGA, Bamboo underwrites, prices and administers home-insurance policies on behalf of fronting carriers and reinsurers (rather than holding the underwriting risk itself), focused on higher-risk residential markets such as California and Texas.

Company profile compiled from public sources (company filings, rating-agency reports, and press releases) — distinct from the SEC Schedule-of-Investments pricing data below.

5
BDC Lenders
17
Debt Positions

Lenders

SEC filing entity: Bamboo US BidCo LLC

Simtra BioPharma Solutions is held by 5 BDC lenders in our parsed SEC filings: AGTC, ARCC, BXSL, GBDC, OBDC.

Cross-lender loan pricing

Each row is one debt tranche at the BDC’s most recent filing that holds this borrower, widest spread first. Mark is the position’s fair value as a percent of par (100 = par). Spread is shown in basis points over the benchmark in the Rate column, normalized from each filing’s as-reported units — rows quoting different benchmarks are still not directly comparable. Compare like-for-like: a second-lien tranche, a different vintage, or an older filing should price wider even when the credit view is identical — check the Type and Filing columns before reading a gap as disagreement. Source: SEC EDGAR (public).

BDCTypeRateSpread (bps)Mark (% of par)Fair ValueMaturityFiling
AGTC1L Sr SecuredSOFR500100.0$21M2030-092026-05-12
AGTC1L Sr SecuredSOFR500100.0$9M2030-092026-05-12
ARCC1L Sr SecuredSOFR500100.0$34M2030-092026-04-28
ARCC1L Sr SecuredSOFR500100.0$7M2030-092026-04-28
BXSL1L Sr SecuredSOFR50099.0$969K2030-09-302026-05-07
BXSL1L Sr SecuredSOFR500—$401K2030-09-302026-05-07
BXSL1L Sr SecuredSOFR50099.0$104K2030-09-302026-05-07
GBDC1L Sr SecuredSOFR50099.5$1M2030-092026-05-04
GBDC1L Sr SecuredSOFR50099.5$1M2030-092026-05-04
GBDC1L Sr SecuredSOFR50099.5$3M2030-092026-05-04
GBDC1L Sr SecuredSOFR50099.3$410K2030-092026-05-04
GBDC1L Sr SecuredSOFR50099.5$2M2030-092026-05-04
OBDC1L Sr SecuredSOFR500100.0$11M2030-092026-05-06
OBDC1L Sr SecuredSOFR500—$5M2030-092026-05-06
GBDC1L Sr SecuredFIXED——-$3K2029-102026-05-04
OBDC1L Sr Secured———2029-102026-05-06
OBDC1L Sr Secured———2027-072026-05-06

Marks reflect each BDC’s own fair-value estimates as reported to the SEC, not traded prices. Private-credit loans are predominantly Level 3 under ASC 820 — valued from unobservable inputs and determined in good faith by each BDC’s board, so figures are estimates as of the filing date and are not directly comparable across managers. Informational only; not investment advice or a valuation.

Ownership & deal activity

Ownership and acquisition events compiled from public sources and audited against the linked source. Each event links to its source; “(reported)” marks a lower-confidence item. Verify anything material against the original source.

  • divestitureBaxter completes $4.25B divestiture of BioPharma Solutions to Bamboo US BidCo LLC; transaction closes end of Q3 2023Baxter International completed the previously announced sale of all equity interests in Baxter Pharmaceutical Solutions LLC and Baxter Oncology GmbH to Bamboo US BidCo LLC and Bamboo BidCo GmbH for $4.25 billion in cash (approximately $3.96 billion net pre-tax proceeds received at closing).2023-09-29 · $4.2B · per sec.gov
No acquisition, ownership-change, or refinancing headlines for Simtra BioPharma Solutions are in our verified news index yet. Most BDC borrowers are private companies, so ownership events are not always public; absence reflects our indexing coverage, not the borrower’s deal activity.

Headlines mentioning Simtra BioPharma Solutions

We haven’t indexed any headlines that name Simtra BioPharma Solutions. That reflects our news-indexing coverage — not the borrower’s activity — so the absence is not a signal.

Reading this table

When two business development companies lend to the same borrower, comparing how each marks the loan is a starting question, not a verdict. In plain English: a wider spread (e.g. S+575 vs S+525) or a lower mark (e.g. 96 vs 100 cents on the dollar) can mean that lender is pricing in more risk — but marks can also differ for reasons other than a credit view: a different tranche (second lien should price wider than first lien on the same company), a different vintage or entry point, an older filing date, or each manager’s own fair-value methodology. Compare like-for-like — check the Type and Filing columns before reading a gap as disagreement. Each row is one debt position at one BDC’s most recent filing. Source: SEC EDGAR Schedule of Investments (public).

Want to read these numbers like an analyst? Free Oxford Ledge lessons: reading a BDC’s Schedule of Investments, key credit metrics, and the Five Cs of credit analysis.